share_log

Mexico Welcomes Legal CBD: Xebra Brands & ICAN Pave The Way With CBD Supply Deal

Mexico Welcomes Legal CBD: Xebra Brands & ICAN Pave The Way With CBD Supply Deal

墨西哥歡迎合法的CBD:Xebra品牌和ICAN通過CBD供應協議鋪平了道路
Benzinga ·  02/21 11:59

Cannabis company Xebra Brands Ltd. (OTCQB:XBRAF) (CSE:XBRA) (FSE: 9YC0) announced Wednesday it has finalized a CBD supply agreement with ICAN Green S.A. de C.V. to supply CBD isolate to Desart MX S.A. de C.V., a division of Xebra, for use in the manufacturing of legal CBD products in Mexico. This collaboration leverages ICAN's reputation as a leader in cannabis-based products across Latin America.

大麻公司Xebra Brands Ltd.(OTCQB: XBRAF)(CSE: XBRA)(FSE:9YC0)週三宣佈,它已與ICAN Green S.A. de C.V. 敲定了CBD供應協議,向Xebra旗下的Desart MX S.A. de C.V. 供應CBD分離物,用於在墨西哥生產合法的CBD產品。這種合作利用了ICAN作爲拉丁美洲大麻類產品領導者的聲譽。

Details Of The Agreement

協議的細節

Under the terms of the agreement, ICAN will be the exclusive supplier of CBD to Desart MX for two years, with the possibility of automatic annual renewal. This collaboration marks a significant milestone for both companies and underscores their commitment to partnering with the Desart MX, a division of Xebra, the only corporation in Mexico federally approved by the COFEPRIS (Mexican FDA) to import and acquire cannabis seeds, cultivate and harvest cannabis, process and produce cannabis, and sell cannabis products with less than 1% THC, both domestically and through export.

根據協議條款,ICAN將成爲Desart MX的CBD獨家供應商,爲期兩年,並可能每年自動續訂。此次合作對兩家公司來說都是一個重要的里程碑,也凸顯了他們對與Xebra旗下的Desart MX合作的承諾。Xebra是墨西哥聯邦政府批准的唯一一家由COFEPRIS(墨西哥食品藥品管理局)批准的進口和收購大麻種子、種植和收穫大麻、加工和生產大麻以及在國內和通過出口銷售四氫大麻酚含量低於1%的大麻產品的公司。

The agreement's commercial terms, based on a per-kilogram pricing model with discounts for larger purchases, reflect a strategic approach to market penetration and growth.

該協議的商業條款基於每千克的定價模型,大宗購買可享受折扣,反映了實現市場滲透和增長的戰略方針。

Management Comments On The Agreement

管理層對協議的評論

Erick Ponce, CEO of ICAN and director of Xebra expressed his enthusiasm about the partnership. "This agreement exemplifies our commitment to Xebra and our desire to continue forward in growing the legal CBD products market in Mexico, and we look forward to supporting Desart MX in their endeavours," Ponce said.

ICAN首席執行官兼Xebra董事埃裏克·龐塞表達了他對合作的熱情。龐塞說:“該協議體現了我們對Xebra的承諾以及我們繼續發展墨西哥合法CBD產品市場的願望,我們期待着支持Desart MX的努力。”

Similarly, Rodrigo Gallardo, interim CEO of Xebra and Desart MX, emphasized the agreement's role in accelerating the commercialization process of CBD products in Mexico, bypassing the need for in-house CBD harvesting and extraction.

同樣,Xebra和Desart MX的臨時首席執行官羅德里戈·加拉多強調了該協議繞過內部CBD收穫和提取的需求,在加速墨西哥CBD產品的商業化過程中的作用。

Both Xebra and ICAN view this partnership as a catalyst for strengthening their market positions and driving success in the burgeoning Mexican CBD industry.

Xebra和ICAN都將這種夥伴關係視爲鞏固其市場地位和推動蓬勃發展的墨西哥CBD行業取得成功的催化劑。

XBRAF Price Action

XBRAF 價格走勢

XBRAF's shares were trading at $0.037 per share at the time of this writing around 11 AM ET Wednesday.

在撰寫本文時,XBRAF的股票交易價格爲每股0.037美元,美國東部時間週三上午11點左右。

Related News

相關新聞

  • Latest Cannabis Hires: Three New CEOs And More
  • Cannabis Opportunity: Xebra Brands Announces $1M Non-Brokered Private Placement Deal
  • 最新大麻招聘:三位新任首席執行官及更多
  • 大麻機會:Xebra Brands宣佈100萬美元的非經紀私募協議

Photo: Benzinga edit with Zero Degree 247 and MR.Yanukit on Shutterstock

照片:Benzinga 在 Shutterstock 上以 Zero Degree 247 剪輯和 Mr.Yanukit


The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.Get your tickets now on bzcannabis.com – Prices will increase very soon!

本辛加大麻資本會議將於2024年4月16日和17日在佛羅里達州好萊塢的新地點重返佛羅里達州。在外交官海灘度假村舉行的爲期兩天的活動將爲大小企業家提供交流、學習和成長的機會。以其引領潮流的能力和對大麻未來的影響而聞名,記住你的日曆——這次會議是大麻界年度必去的活動。立即在bzcannabis.com上購買門票——價格很快就會上漲!

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論